Review of regulatory requirements in the US, EU and Serbia on software: Mobile application as a medical device: State of the art

Q4 Pharmacology, Toxicology and Pharmaceutics Arhiv za Farmaciju Pub Date : 2022-01-01 DOI:10.5937/arhfarm72-36730
Dušan Vukmirović, I. Stević, M. Odalović, Dušanka M. Krajnović
{"title":"Review of regulatory requirements in the US, EU and Serbia on software: Mobile application as a medical device: State of the art","authors":"Dušan Vukmirović, I. Stević, M. Odalović, Dušanka M. Krajnović","doi":"10.5937/arhfarm72-36730","DOIUrl":null,"url":null,"abstract":"The number of software - mobile applications intended for use in the field of people's health and well-being is constantly increasing. The aim of this review is to compare regulations on software - mobile applications as medical devices in the United States of America (USA), European Union (EU) and Serbia, with reference on the efforts for international harmonization of the regulations. The goal is to increase awareness of the broader healthcare professionals' (HCPs) audience about this topic. Publicly available information from official regulatory bodies websites was analyzed and synthesized for two regions and one country of interest. The results show differences in regulatory approaches in this area between two biggest medical device markets - the USA and the EU, while regulations in Serbia are being harmonized with the EU. Regulations clearly define criteria that software - mobile application needs to meet to be assessed as a medical device; on the other hand, they leave a number of applications that provide health-related services out of the regulated scope. Based on the increased awareness of regulations, recommendations for future research can be directed towards greater involvement of HCPs in patient counseling and decision making regarding the selection of mobile applications, to prevent the use of inadequate mobile applications and ensure that their patients are correctly using the right applications with positive effects on health and well-being.","PeriodicalId":39173,"journal":{"name":"Arhiv za Farmaciju","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arhiv za Farmaciju","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5937/arhfarm72-36730","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

The number of software - mobile applications intended for use in the field of people's health and well-being is constantly increasing. The aim of this review is to compare regulations on software - mobile applications as medical devices in the United States of America (USA), European Union (EU) and Serbia, with reference on the efforts for international harmonization of the regulations. The goal is to increase awareness of the broader healthcare professionals' (HCPs) audience about this topic. Publicly available information from official regulatory bodies websites was analyzed and synthesized for two regions and one country of interest. The results show differences in regulatory approaches in this area between two biggest medical device markets - the USA and the EU, while regulations in Serbia are being harmonized with the EU. Regulations clearly define criteria that software - mobile application needs to meet to be assessed as a medical device; on the other hand, they leave a number of applications that provide health-related services out of the regulated scope. Based on the increased awareness of regulations, recommendations for future research can be directed towards greater involvement of HCPs in patient counseling and decision making regarding the selection of mobile applications, to prevent the use of inadequate mobile applications and ensure that their patients are correctly using the right applications with positive effects on health and well-being.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
审查美国、欧盟和塞尔维亚对软件的监管要求:作为医疗设备的移动应用程序:最新状况
用于人们健康和福祉领域的软件-移动应用程序的数量不断增加。本审查的目的是比较美利坚合众国(美国)、欧洲联盟(欧盟)和塞尔维亚将软件-移动应用程序作为医疗设备的法规,并参考这些法规的国际协调努力。目标是提高更广泛的医疗保健专业人员(HCPs)受众对该主题的认识。对两个区域和一个有关国家的官方管理机构网站上的公开信息进行了分析和综合。研究结果表明,美国和欧盟这两个最大的医疗器械市场在这一领域的监管方法存在差异,而塞尔维亚的监管正在与欧盟协调一致。法规明确定义了移动软件应用程序需要满足的标准,才能被评估为医疗设备;另一方面,它们将一些提供健康相关服务的应用程序排除在监管范围之外。基于对法规意识的提高,对未来研究的建议可以指向卫生保健服务提供者更多地参与患者咨询和关于选择移动应用程序的决策,以防止使用不适当的移动应用程序,并确保其患者正确使用正确的应用程序,对健康和福祉产生积极影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Arhiv za Farmaciju
Arhiv za Farmaciju Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
自引率
0.00%
发文量
19
审稿时长
12 weeks
期刊最新文献
The Mediterranean diet and lifestyle Dietary antioxidants and health effects: What are their optimal intakes? Antioxidant activity of plant secondary metabolites Methods for the determination of antioxidant activity of plant extracts in vitro Cardiotoxicity: Importance of biomarkers
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1